These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11524494)

  • 41. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.
    Wolinsky JS; Comi G; Filippi M; Ladkani D; Kadosh S; Shifroni G;
    Neurology; 2002 Oct; 59(8):1284-6. PubMed ID: 12391370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 45. Glatiramer acetate in the treatment of multiple sclerosis.
    Sela M; Teitelbaum D
    Expert Opin Pharmacother; 2001 Jul; 2(7):1149-65. PubMed ID: 11583066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate.
    Aktas O; Ari N; Rieks M; Hoffmann V; Schimrigk S; Przuntek H; Pöhlau D
    Acta Neurol Scand; 2001 Nov; 104(5):266-70. PubMed ID: 11696019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
    Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
    Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.
    Brown RA; Narayanan S; Stikov N; Cook S; Cadavid D; Wolansky L; Arnold DL
    Neurology; 2016 Aug; 87(9):905-11. PubMed ID: 27473139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.
    Biegler BW; Yan SX; Ortega SB; Tennakoon DK; Racke MK; Karandikar NJ
    J Neuroimmunol; 2006 Nov; 180(1-2):159-71. PubMed ID: 16935352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
    Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
    Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
    Arnold DL; Narayanan S; Antel S
    J Neurol; 2013 Jul; 260(7):1901-6. PubMed ID: 23589190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
    Fragoso YD; Finkelsztejn A; Kaimen-Maciel DR; Grzesiuk AK; Gallina AS; Lopes J; Morales NM; Alves-Leon SV; de Almeida SM
    CNS Drugs; 2010 Nov; 24(11):969-76. PubMed ID: 20806993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.